The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2010 Help me understand this report
Rituximab monotherapy in relapsed lymphocyte-predominant Hodgkin’s lymphoma
Abstract: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) accounts for approximately 5% of Hodgkin's lymphoma, presents with early-stage disease and has an indolent course. Treatment is not well established. We present a patient diagnosed with NLPHL and treated with Rituximab second-line therapy after chemotherapy.
Search citation statements
Paper Sections
Select...
Citation Types
0
0
0
Year Published
2011
2011
Publication Types
Select...
1
Relationship
0
1
Authors
Journals
Cited by 1 publication
References 12 publications
(11 reference statements)
0
0
0
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
